Development and Validation of a Nomogram to Predict Significant Liver Inflammation in Patients with Chronic Hepatitis B

References

• Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2):e00046–19.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis. 2018;12(1):33–34. doi:10.1002/cld.728
   PubMedGoogle Scholar
• Brody H. Hepatitis B. Nature. 2022;603(7903):S45. doi:10.1038/d41586-022-00811-2
   PubMed Web of Science ®Google Scholar
• Bengsch B, Chang KM. Evolution in our understanding of hepatitis b virus virology and immunology. Clin Liver Dis. 2016;20(4):629–644. doi:10.1016/j.cld.2016.06.001
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Kramvis A, Chang KM, Dandri M, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19(11):727–745. doi:10.1038/s41575-022-00649-z
   PubMed Web of Science ®Google Scholar
• Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017–1044. doi:10.1002/hep.22742
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36. doi:10.1002/hep.21669
   PubMed Web of Science ®Google Scholar
• Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65(8):1369–1376. doi:10.1136/gutjnl-2015-309260
   PubMed Web of Science ®Google Scholar
• Seto WK, Lai CL, Ip PP, et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One. 2012;7(2):e32622. doi:10.1371/journal.pone.0032622
   PubMed Web of Science ®Google Scholar
• Chao DT, Lim JK, Ayoub WS, et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014;39(4):349–358. doi:10.1111/apt.12590
   PubMed Web of Science ®Google Scholar
• Wang J, Xia J, Yan X, et al. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol. 2020;44(6):913–922. doi:10.1016/j.clinre.2020.01.011
   PubMed Web of Science ®Google Scholar
• Teng J, Du Y, Visalath P, et al. A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT. Virol J. 2023;20(1):7. doi:10.1186/s12985-023-01963-x
   PubMed Web of Science ®Google Scholar
• Zhao XA, Wang J, Wei J, et al. Gamma-glutamyl transpeptidase to platelet ratio predicts liver injury in hepatitis B e antigen-negative chronic hepatitis b patients with normal alanine aminotransferase. J Clin Transl Hepatol. 2022;10(2):247–253. doi:10.14218/JCTH.2021.00151
   PubMed Web of Science ®Google Scholar
• Duan M, Chi X, Xiao H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int. 2021;15(2):318–327. doi:10.1007/s12072-021-10153-2
   PubMed Web of Science ®Google Scholar
• Pokorska-śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, et al. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment. Clin Exp Hepatol. 2017;3(4):187–193. doi:10.5114/ceh.2017.71079
   PubMed Web of Science ®Google Scholar
• Yakoob R, Bozom IA, Thandassery RB, et al. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the middle east experience. Ann Gastroenterol. 2015;28(2):265–270.
   PubMedGoogle Scholar
• Uyar C, Akcam FZ, Ciris M, et al. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C. Indian J Pathol Microbiol. 2010;53(3):470–475. doi:10.4103/0377-4929.68281
   PubMed Web of Science ®Google Scholar
• Yao M, Wang L, Wang J, et al. Diagnostic value of serum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis. Dis Markers. 2022;2022:4253566. doi:10.1155/2022/4253566
   PubMed Web of Science ®Google Scholar
• Xu WS, Qiu XM, Ou QS, et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine. 2015;94(10):e612. doi:10.1097/MD.0000000000000612
   PubMed Web of Science ®Google Scholar
• Yao K, Wang J, Wang L, et al. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol. 2022;94(2):659–666. doi:10.1002/jmv.27327
   PubMed Web of Science ®Google Scholar
• Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540–1550.
   PubMed Web of Science ®Google Scholar
• Chang X, Wang J, Chen Y, et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine. 2021;67:103389. doi:10.1016/j.ebiom.2021.103389
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang FD, Wang ML, et al. Antiviral therapy for chronic HBV infection with persistently normal alanine aminotransferase: controversy and consensus. Front Med. 2021;8:717125. doi:10.3389/fmed.2021.717125
   Web of Science ®Google Scholar
• Zhang L, Yang L, Gao Y, et al. Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT. Virulence. 2023;14(1):2158710. doi:10.1080/21505594.2022.2158710
   PubMed Web of Science ®Google Scholar
• Chen S, Huang H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front Med. 2021;8:661725. doi:10.3389/fmed.2021.661725
   Web of Science ®Google Scholar
• Li Q, Zhou Y, Huang C, et al. A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. Sci Rep. 2018;8(1):15449. doi:10.1038/s41598-018-33412-z
   PubMedGoogle Scholar
• Gui HL, Wang H, Yang YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat. 2010;17 Suppl 1:44–50. doi:10.1111/j.1365-2893.2010.01270.x
   PubMed Web of Science ®Google Scholar
• Myers RP, Ratziu V, Imbert-Bismut F, et al. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97(9):2419–2425. doi:10.1111/j.1572-0241.2002.05997.x
   PubMed Web of Science ®Google Scholar
• Eminler AT, Irak K, Ayyildiz T, et al. The relation between liver histopathology and GGT levels in viral hepatitis: more important in hepatitis B. Turk J Gastroenterol. 2014;25(4):411–415. doi:10.5152/tjg.2014.3693
   PubMed Web of Science ®Google Scholar
• Kim SU, Han KH, Park JY, et al. Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver Int. 2009;29(6):810–815. doi:10.1111/j.1478-3231.2008.01894.x
   PubMed Web of Science ®Google Scholar
• Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology. 2022;75(6):1373–1385. doi:10.1002/hep.32283
   PubMed Web of Science ®Google Scholar
• Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18036. doi:10.1038/nrdp.2018.36
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J, Yan X, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol Commun. 2022;6(4):855–866. doi:10.1002/hep4.1859
   PubMed Web of Science ®Google Scholar
• Kattan MW, Scardino PT. Evidence for the usefulness of nomograms. Nat Clin Pract Urol. 2007;4(12):638–639. doi:10.1038/ncpuro0968
   PubMedGoogle Scholar